# OCT 1 1 2007

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of

Joel R. Studin

Serial No.

10/829,316

Filed

April 21, 2004

Examiner

Sheikh, Humera N.

Art Unit

1615

Title

Method and Composition for the Treatment of Scars

Commissioner of Patents and Trademarks P.O. Box 1450 Alexandria, VA 22313-1450

## DECLARATION OF JOEL R. STUDIN UNDER 37 C.F.R. §1.131

### I do hereby declare as follows:

- 1. THAT I received a Bachelor of Science in General Science and Psychology from the University of Rochester, Rochester, NY, in 1975.
- 2. THAT I received a Doctor of Medicine from Mount Sinai Hospital, New York, NY, in 1982.
- 3. THAT I have practiced as a Plastic and Reconstructive Surgeon since 1987.
- 4. THAT I am the inventor of the above-identified application, that I am familiar with the above-identified application, the Office Actions and applied references rendered to date.
- THAT Exhibit A is a Formula Worksheet from an independent laboratory I directed to prepare a formulation called Scar Guard, containing a corticosteroid in a film-forming carrier, prior to September 28, 1999. See Exhibit A, from which all dates and extraneous information have been redacted.
- 6. THAT Exhibit B is a Stability Report Sheet which shows stability testing results of Scar Guard formulation prior to September 28, 1999. See Exhibit B, from which all dates and extraneous information have been redacted.
- THAT Exhibit C is a Facsimile Cover Page from an independent testing facility I directed to test Scar Guard, showing that Scar Guard was applied

to skin to treat a skin condition and that corticosteroid was transferred into the skin, prior to September 28, 1999. See Exhibit C, from which all dates and extraneous information have been redacted.

8. I further declare that all statements made herein to my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements so made may jeopardize the validity of the document, or application, or any patent issuing therefrom.

Respectfully submitted,

8/20/07

Date

.

Joel R. Studin

	RIES, INC.		
THE PROPERTY OF THE PROPERTY O	LA WORKSHEET ***	_ ,,,	ge: 1
		=========	
Days to exp. : 360 Estima Where obtained: DFG Date: Misc.: Therapy: Date made: _/_/ Mage Exp. date:/_/ Lot not not be a considered as a constant of the con	r MLS: \$.658 as o.  tod time to make:	Verified by:_Qty made:	100 MLS
roine Form qu		exp. Date Mig	ing.Cost
XANTHAN GUM 525G 1055 PWDR	.200 GMS	/	\$.0104
1 GMS / #500 (formula qty) x #100 (qty made HYDROCORTISONE MICONIZED (\$\frac{\text{Sind} \text{U} \cdot \text{Vision}}{\text{U} \text{PMDR}} \rightarrow \text{PMDR} 5 GMS / #500 (formula qty) x #100 (qty made	) = .2 GMS 1.000 GMS:		
SILICONE FLUID 556 1,500 LIQ		1	\$1,7000
50 MLS / #500 (formula qty) x #100 (qty mad			
SOLN			\$2.1600
" 450 MLS / #500 (formula qty) x #100 (qty ma			
* # BRUSH APPLICATOR 15 ML SUPL		/	\$3.6040
34 UNIT / #500 (formula qty) x #100 (qty ma Es	de) = 6.8 UNIT timated profit per batch \$	57.26 Total inc	cnst \$8 54

### ----INSTRUCTIONS/NOTES-----

- 1. PUT XANTHAN GUM & HC POWDER IN MORTAR & MIX WELL.
- 2. SLOWLY ADD SILICONE, MIXING WELL
- 3. SLOWLY ADD ABOUT 100ML OF FLEX COLLODION, MIXING WELL.
- 4. POUR RESULTANT MIXTURE IN A JAR & ADD REMAINING FLEX COLLODION AND SHAKE VIGOROUSLY UNTIL RESULTANT LIQUID IS HOMOGENIOUS.
- 5. SHAKE WELL & POUR SMALL AMOUNT INTO A BEAKER AND FILL 15ML BRUSH BOTTLES KEEP SHAKING & FILLING UNTIL ALL BOTTLES ARE FULL.

# Stability Report Sheet

Produc	ct Description t Lab Numbe	r G229				
Date	Manufacture Date Bottle	d Unknow	n			
		-	<del></del>			
	Date started	Time in	Time out	Date		
Ref Standard		,	11110 001	Completed	Cornments	Pass/Fail
Dark Stability				<del> </del>		
Light Stability		d		<del>                                     </del>		YN
Oven Stability				,		YN
menth 1		4:00pm	1:30Pm		Vallania	
month 2			1	-	Yellow, sediment, off-color the	YO
क्रावासक व						YN
month 4						<u> Y N</u>
Freeze/Thaw	· <del></del>			,		] Y N
Cycle 1		9:23AM	4:06PM			
Cycle 2		4:12PM	9:35AM		2ass	(V) N
Cycle s		10:01AM	و و د و چه د و اهم و الاو و د و و ۱۵ و ۱۵ و ۱۵ و ۱۵ و ۱۵ و ۱۵ و		P953	(P) N
Cool/Heat		TO CO I PAIN	14.03710	*	Pass	(1) N
<u>۳</u>		offere of the large of the	Carrier of the Contract of the	-		
Cypte t	j	e:Cuan	H.COFN		pade	(V)
Cycle 2	4	S:CCAN	HIZOPM		Pass	(V) N
Oyeld S		MAGO.E	4:09PM		কৈবঙ্	
UV Stability				<del></del> ,	***************************************	111
Cycle 1		000AM	(2:00FM	—— т	358	
Cycle 2	~		4:00PM		766	Y N
Cycle ă	· ' '!	OCPM	10:00AM		ail - Color change to yellow	UN N
Cycle 4	t				- Contractings to year.	YON
					10.0	4. 4
The above enalysis w	ere complete:	1 by	Robert Keele			
The above analysis is	aborathu pos					
		mocks sec	a pentinant info	, gew notianno	raviowed and the results ventied b	ur .
_	The state of the s		S		on_	
This product (PASS	FAIL) he abo	ve stabilit	Villing EA	グ	-	
-	The state of the s		andreis tide man	137	DATE	W-LO.



Tel: Fax:

	COVENAGE		
To: Christine (Business Fax)	From: Zane Last		
Fax #:	Fax #:		
Company: Red Rocks Laboratories, Inc.	Tel #:		
Subject: Scar Guard & Validation			
Sent:	Pages: 1 (including cover)		

### MESSAGE:

Christine,

We are able to verify the amount of hydrocortisone in the collodion base as part of the validity and stability testing. While your clinical testing on psoriasis indicated that there was a transfer of the corticosteroid into the skin, your request to assay the actual potency of the delivery of corticosteroids for skin conditions such as psoriasis and eczema would have to be outsourced as they involve either animal or human studies.

Please let me know if you would like us to send this out for quotes.

Thank You,

Zane Last R. Ph.

**Confidentiality Notice** 

This communication is intended for the sole use of the individual to whom it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient, or the employee or the agent for delivering the communication to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone call and return the communication to the address above via the United States Postal Service. Thank you.